To better help fight the Omicron variant of COVID-19, the U.S. Food and Drug Administration has issued an Emergency Use Authorization for bivalent COVID-19 vaccine for booster doses. This was followed by Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices’ recommendation for use of the Pfizer bivalent booster vaccine for ages … Read more

Gene therapies have yielded promising results for individuals experiencing rare diseases. However, these groundbreaking therapies come with their own unique set of challenges regarding who will be able to access them, how much they will cost, and how the policymaking and scientific processes will conflict as more and more therapies undergo clinical trials.     … Read more

Last month’s 2021 Colorado State of Reform Health Policy Conference saw numerous forward-thinking and productive conversations around how to improve the state’s health care system. A big thank you to all of our speakers and everyone who attended the event! Read about some of the event highlights below. Please don’t hesitate to send me feedback or story ideas. Thanks for reading! … Read more

Gene therapy has proven to be a promising treatment for rare diseases like muscular dystrophy. As these life-saving treatments enter the market, however, their high costs pose affordability challenges for individuals living with rare diseases.     In our upcoming virtual conversation, “5 Slides: Gene therapy and the promise for rare disease,” we will host … Read more

Bhash Parasuraman, vice president of value and access for rare disease and internal medicine at Pfizer, joined State of Reform on Thursday for a conversation on the future of gene therapy.  As part of our virtual “Leadership Series,” Parasuraman discussed the outlook for gene therapy, the policies she’d like to see to support these treatments, … Read more